Biotech Values

[DewDiligence]

I_consider_all_five—(RVNC, ENTA, ABT, BMY, PFE)—to_be_buys at their current valuations, but there is a wide disparity in risk and upside potential: ENTA is riskiest and has the most upside potential; RVNC ranks next on both metrics; BMY and PFE are pretty safe but have patent-expiration issues; and ABT is a “widows and orphans” stock that you won’t lose any sleep over.